ProPhase Labs (PRPH)
(Real Time Quote from BATS)
$2.45 USD
+0.11 (4.70%)
Updated Sep 23, 2024 01:14 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
ProPhase Labs, Inc. [PRPH]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Repeating Successful Emerging Growth Playbook with Advanced ManufacturingUpgrades
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Disruptive Innovations in Cancer Treatment and Diagnostics with Project ZenQ-AI and BE-Smart Test Targeting Large Addressable Markets
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
2023 Financial Results; Update Rating to Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Esophageal Cancer Test On Track to Complete Clinical Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Equivir Trial Reports Positive Preliminary Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
SUBSIDIARY, PHARMALOZ MANUFACTURING - A HIGH-GROWTH, EXPERIENCED CDMO MANUFACTURER
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Notable Developments Across Multiple Subsidiaries with Numerous Ways to Unlock Potential Shareholder Value
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
3Q23 Financial Results Reported; Reiterate Buy; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Pharmaloz Manufacturing Capacity to Expand Significantly to Satisfy Market Demand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Consumer Product Business Leading from the Front with Advancing Development of BE-Smart Pre-Cancer Diagnostic and Linebacker Therapeutics
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Linebacker-1 Inhibits Cancer Cell Growth in Preclinical Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Promising Linebacker Pre-Clinical Results, While Operational Execution Continues
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
1Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Lowest-Ever Pricing Introduced For Personal Whole Genome Sequencing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Clinical Trial of OTC Antiviral Supplement Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Contract Manufacturing Capacity Expanded to Meet Growing Demand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y